Determination of half maximal inhibitory concentration (IC50) of several anticancer drugs for inhibiting CYP3 A 4 metabolism of midazolam Cytochrome P450 3 A 4 (CYP3 A 4) is responsible for metabolizing approximately 40-50% of pharmaceutically active ingredients; this includes some very important anticancer agents that could interact with concomitant medications that are also CYP3 A 4 substrates given their narrow therapeutic window.
Ákvörðun á IC50 gildi krabbameinslyfja fyrir hamningu á umbroti mídazólams gegnum CYP3 A 4 Cýtókróm P450 3 A 4 (CYP3 A 4) sér um niðurbrot á 40–50 % af öllum lyfjum. Þar á meðal eru mikilvæg krabbameinslyf sem geta milliverkað við önnur lyf sem eru gefin samhliða og eru einnig brotin niður af CYP3 A 4.